AstraZeneca AB

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

We employ around 51,500 people worldwide: 34.8% in Europe, 21.7% in North America, 6% in Central and South America, 4.1% in the Middle East and Africa and 33.4% in Asia Pacific. We manufacture in 16 countries and are committed to ensuring a reliable supply of medicines where and when they are needed. We work in over 100 countries and our medicines are used by millions of patients worldwide.

Key staff involved in EBiSC

Jonathan Wrigley (Associate Director) – Cell Reagents & Assay Development

Gabriella Brolén (Team leader) – iPSC, Primary cells, Stem cells and Assay development Team

Anna Jonebring (Senior scientist iPSC) – Primary cells, Stem cells and Assay development Team

More information: www.astrazeneca.com »